124 related articles for article (PubMed ID: 32521616)
21. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
22. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.
Alteri C; Scutari R; Bertoli A; Armenia D; Gori C; Fabbri G; Mastroianni CM; Cerva C; Cristaudo A; Vicenti I; Bruzzone B; Zazzi M; Andreoni M; Antinori A; Svicher V; Ceccherini-Silberstein F; Perno CF; Santoro MM
Virus Genes; 2019 Jun; 55(3):290-297. PubMed ID: 30796743
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Lake JE; Wu K; Bares SH; Debroy P; Godfrey C; Koethe JR; McComsey GA; Palella FJ; Tassiopoulos K; Erlandson KM
Clin Infect Dis; 2020 Dec; 71(9):e471-e477. PubMed ID: 32099991
[TBL] [Abstract][Full Text] [Related]
24. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
De Francesco MA; Izzo I; Properzi M; Gargiulo F; Caccuri F; Quiros-Roldan E; Castelli F; Caruso A; Focà E
AIDS Res Hum Retroviruses; 2018 Jul; 34(7):570-574. PubMed ID: 29631420
[TBL] [Abstract][Full Text] [Related]
26. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G
J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.
Davy-Mendez T; Napravnik S; Zakharova O; Wohl DA; Farel CE; Eron JJ
AIDS; 2019 Jun; 33(7):1187-1195. PubMed ID: 30870198
[TBL] [Abstract][Full Text] [Related]
28. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G
Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291
[TBL] [Abstract][Full Text] [Related]
29. Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood Products.
Kawado M; Hashimoto S; Oka SI; Fukutake K; Higasa S; Yatsuhashi H; Ogane M; Okamoto M; Shirasaka T
Open AIDS J; 2017; 11():18-23. PubMed ID: 28553428
[TBL] [Abstract][Full Text] [Related]
30. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
31. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
32. Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy.
Galdamez R; García JA; Fernández M; Robledano C; Agulló V; García-Abellán J; Telenti G; Padilla S; Gutiérrez F; Masiá M
Open Forum Infect Dis; 2019 Dec; 6(12):ofz491. PubMed ID: 32128334
[TBL] [Abstract][Full Text] [Related]
33. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
34. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
Marcelin AG; Grude M; Charpentier C; Bellecave P; Le Guen L; Pallier C; Raymond S; Mirand A; Bocket L; Fofana DB; Delaugerre C; Nguyen T; Montès B; Jeulin H; Mourez T; Fafi-Kremer S; Amiel C; Roussel C; Dina J; Trabaud MA; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Maillard A; Ferre V; Descamps D; Calvez V; Flandre P;
J Antimicrob Chemother; 2019 May; 74(5):1368-1375. PubMed ID: 30789205
[TBL] [Abstract][Full Text] [Related]
35. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
36. Integrase Strand Transfer Inhibitors Play the Main Role in Greater Weight Gain Among Men With Acute and Early HIV Infection.
Wu KS; Anderson C; Little SJ
Open Forum Infect Dis; 2021 Jan; 8(1):ofaa619. PubMed ID: 33511237
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Integrase Strand Inhibitor Resistance (INSTI)in New Orleans, Louisiana, 2012-2013.
Jeanfreau K; Sharma S; Frontini M; Khirfan M; Clark RA
J La State Med Soc; 2015; 167(1):19-20. PubMed ID: 25978751
[TBL] [Abstract][Full Text] [Related]
38. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
39. Primary resistance to integrase strand-transfer inhibitors in Europe.
Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
[TBL] [Abstract][Full Text] [Related]
40. Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.
Jeong W; Jung IY; Choi H; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Kim JM; Choi JY
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):213-216. PubMed ID: 30229661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
